Corient Capital Partners LLC lessened its position in Danaher Co. (NYSE:DHR) by 19.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,607 shares of the conglomerate’s stock after selling 4,442 shares during the quarter. Corient Capital Partners LLC’s holdings in Danaher were worth $2,457,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DHR. Reynders McVeigh Capital Management LLC boosted its position in Danaher by 2.8% during the first quarter. Reynders McVeigh Capital Management LLC now owns 243,152 shares of the conglomerate’s stock valued at $32,101,000 after buying an additional 6,519 shares during the period. Bluestein R H & Co. boosted its position in Danaher by 60.0% during the first quarter. Bluestein R H & Co. now owns 4,000 shares of the conglomerate’s stock valued at $528,000 after buying an additional 1,500 shares during the period. Zions Bancorporation N.A. purchased a new stake in Danaher during the first quarter valued at about $177,000. Swiss National Bank boosted its position in Danaher by 2.9% during the first quarter. Swiss National Bank now owns 2,532,844 shares of the conglomerate’s stock valued at $334,386,000 after buying an additional 70,300 shares during the period. Finally, Norinchukin Bank The boosted its position in Danaher by 4.8% during the first quarter. Norinchukin Bank The now owns 151,114 shares of the conglomerate’s stock valued at $19,950,000 after buying an additional 6,923 shares during the period. 78.82% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE DHR traded up $0.94 on Friday, reaching $142.92. 3,777,817 shares of the company’s stock traded hands, compared to its average volume of 2,190,275. Danaher Co. has a 12 month low of $94.59 and a 12 month high of $144.57. The company has a 50 day moving average of $135.57. The stock has a market cap of $102.32 billion, a P/E ratio of 31.62, a price-to-earnings-growth ratio of 2.74 and a beta of 0.95. The company has a current ratio of 2.18, a quick ratio of 1.74 and a debt-to-equity ratio of 0.32.
The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a dividend yield of 0.48%. The ex-dividend date is Thursday, June 27th. Danaher’s dividend payout ratio (DPR) is currently 15.04%.
In other Danaher news, Director Alan G. Spoon sold 1,913 shares of Danaher stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $129.52, for a total value of $247,771.76. Following the completion of the sale, the director now owns 86,863 shares of the company’s stock, valued at approximately $11,250,495.76. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Chairman Mitchell P. Rales bought 1,900 shares of the business’s stock in a transaction on Friday, May 10th. The stock was bought at an average cost of $130.78 per share, with a total value of $248,482.00. The disclosure for this purchase can be found here. Insiders have sold 453,448 shares of company stock valued at $59,724,640 in the last three months. 11.40% of the stock is owned by insiders.
A number of analysts have recently weighed in on DHR shares. JPMorgan Chase & Co. reiterated an “overweight” rating and set a $140.00 target price on shares of Danaher in a report on Monday, March 4th. Janney Montgomery Scott increased their target price on shares of Danaher from $136.00 to $174.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Piper Jaffray Companies started coverage on shares of Danaher in a report on Tuesday, June 11th. They set a “neutral” rating and a $148.00 target price for the company. Zacks Investment Research upgraded shares of Danaher from a “sell” rating to a “hold” rating in a report on Monday, May 6th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $141.00 target price (up from $138.00) on shares of Danaher in a report on Wednesday, April 17th. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $133.00.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.